Skip to main content
. 2024 Sep 30;16(19):3353. doi: 10.3390/cancers16193353

Figure 3.

Figure 3

RFS according to tumor immune microenvironment (TiME) biomarkers and adjuvant chemotherapy. (A) CD8 expression, (B) CXCR3 expression and (C) Immune phenotype.